Literature DB >> 15545995

A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

Nathalie Vergnolle1, Laurie Cellars, Andrea Mencarelli, Giovanni Rizzo, Sunita Swaminathan, Paul Beck, Martin Steinhoff, Patricia Andrade-Gordon, Nigel W Bunnett, Morley D Hollenberg, John L Wallace, Giuseppe Cirino, Stefano Fiorucci.   

Abstract

Proteinase-activated receptor-1 (PAR1), a G protein-coupled receptor activated by thrombin, is highly expressed in different cell types of the gastrointestinal tract. The activity of thrombin and of other proteinases is significantly increased in the colon of inflammatory bowel disease (IBD) patients. Since PAR1 activation in tissues other than the gut provoked inflammation, we hypothesized that PAR1 activation in the colon is involved in the pathogenesis of IBD. Here, we demonstrate that PAR1 is overexpressed in the colon of IBD patients. In mice, intracolonic administration of PAR1 agonists led to an inflammatory reaction characterized by edema and granulocyte infiltration. This PAR1 activation-induced inflammation was dependent on B and T lymphocytes. Moreover, PAR1 activation exacerbated and prolonged inflammation in a mouse model of IBD induced by the intracolonic administration of trinitrobenzene sulfonic acid (TNBS), while PAR1 antagonism significantly decreased the mortality and severity of colonic inflammation induced by TNBS and dextran sodium sulfate. In these 2 models, colitis development was strongly attenuated by PAR1 deficiency. Taken together, these results imply an important role for PAR1 in the pathogenesis of experimental colitis, supporting the notion that PAR1 inhibition may be beneficial in the context of IBD and possibly in other chronic intestinal inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545995      PMCID: PMC526028          DOI: 10.1172/JCI21689

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.

Authors:  H C Zhang; C K Derian; P Andrade-Gordon; W J Hoekstra; D F McComsey; K B White; B L Poulter; M F Addo; W M Cheung; B P Damiano; D Oksenberg; E E Reynolds; A Pandey; R M Scarborough; B E Maryanoff
Journal:  J Med Chem       Date:  2001-03-29       Impact factor: 7.446

2.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.

Authors:  M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 3.  Protease-activated receptors in inflammation, neuronal signaling and pain.

Authors:  N Vergnolle; J L Wallace; N W Bunnett; M D Hollenberg
Journal:  Trends Pharmacol Sci       Date:  2001-03       Impact factor: 14.819

Review 4.  Proteinase-activated receptors.

Authors:  S R Macfarlane; M J Seatter; T Kanke; G D Hunter; R Plevin
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

5.  Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells.

Authors:  G Sun; M A Stacey; M Schmidt; L Mori; S Mattoli
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

6.  Arginine-specific protease from Porphyromonas gingivalis activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion.

Authors:  A Lourbakos; J Potempa; J Travis; M R D'Andrea; P Andrade-Gordon; R Santulli; E J Mackie; R N Pike
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells.

Authors:  M C Buresi; E Schleihauf; N Vergnolle; A Buret; J L Wallace; M D Hollenberg; W K MacNaughton
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-08       Impact factor: 4.052

8.  Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.

Authors:  M D Hollenberg; M Saifeddine; B al-Ani; A Kawabata
Journal:  Can J Physiol Pharmacol       Date:  1997-07       Impact factor: 2.273

9.  Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis.

Authors:  S Fiorucci; A Mencarelli; B Palazzetti; E Distrutti; N Vergnolle; M D Hollenberg; J L Wallace; A Morelli; G Cirino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

10.  Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism.

Authors:  L de Garavilla; N Vergnolle; S H Young; H Ennes; M Steinhoff; V S Ossovskaya; M R D'Andrea; E A Mayer; J L Wallace; M D Hollenberg; P Andrade-Gordon; N W Bunnett
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

View more
  36 in total

1.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

2.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 3.  Clinical relevance of proteinase activated receptors (pars) in the gut.

Authors:  N Vergnolle
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 4.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

5.  Inhibition of protease-activated receptor 1 ameliorates intestinal radiation mucositis in a preclinical rat model.

Authors:  Junru Wang; Ashwini Kulkarni; Madhu Chintala; Louis M Fink; Martin Hauer-Jensen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-12       Impact factor: 7.038

Review 6.  The protein C pathway and pathologic processes.

Authors:  F J Castellino; V A Ploplis
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

7.  Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents.

Authors:  Fiore Cattaruzza; Nicolas Cenac; Elisabetta Barocelli; Mariannina Impicciatore; Eric Hyun; Nathalie Vergnolle; Catia Sternini
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 8.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

9.  Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2.

Authors:  Nitsan Maharshak; Eun Young Huh; Chorlada Paiboonrungruang; Michael Shanahan; Lance Thurlow; Jeremy Herzog; Zorka Djukic; Roy Orlando; Rafal Pawlinski; Melissa Ellermann; Luke Borst; Siten Patel; Iris Dotan; Ryan B Sartor; Ian M Carroll
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

Review 10.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.